TABLE III.
REDUCTION IN LIFETIME RISK OF GASTRIC CANCER AND COST-EFFECTIVENESS OF H. pylori SCREENING STRATEGIES FOR OLDER COHORTS
| Cohort age | Gastric cancer incidence reduction, %1 | Men–ICER ($/YLS)2 |
Gastric cancer incidence reduction, %1 | Women–ICER ($/YLS)2 |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Screen | Screen + rescreen once | Screen + rescreen twice | Universal treatment | Screen | Screen + rescreen once | Screen + rescreen twice | Universal treatment | |||
| 20 | 14–16 | $1,340 | Dominated3 | Dominated | $2,720 | 27–30 | $1,230 | Dominated3 | Dominated | $2,510 |
| 30 | 9–10 | $2,050 | Dominated3 | Dominated | $4,030 | 18–20 | $1,710 | Dominated3 | Dominated | $3,420 |
| 40 | 5–6 | $3,940 | Dominated3 | Dominated | $7,530 | 11–12 | $2,790 | Dominated3 | Dominated | $5,460 |
| 50 | 2–3 | $9,420 | Dominated3 | Dominated | $19,020 | 6–7 | $5,430 | Dominated3 | Dominated | $10,560 |
| 60 | 1 | $30,030 | Dominated3 | Dominated | $60,360 | 3 | $13,680 | Dominated3 | Dominated | $24,290 |
1
Range of mean reductions calculated using all 50 good-fitting parameter sets among all H. pylori screening strategies.
2
Calculated as the ratio of the mean-costs divided by the mean-effects of the 50 good-fitting parameter sets for each strategy compared with the next-best strategy. ICER denotes incremental cost-effectiveness ratio. YLS denotes year of life saved.
3
Eliminated because of extended dominance: strategies with a higher incremental cost-effectiveness ratio than a more effective alternative strategy.